Zhaoke Ophthalmology Ltd 2022 SR
The report highlights Zhaoke Ophthalmology's commitment to sustainable biotech development, focusing on its drug pipeline of 26 candidates and advanced manufacturing facility in Nansha. In 2022, the Group conducted a materiality assessment identifying nine key topics, including workplace safety and product quality. Environmental efforts included setting targets for waste and energy, with a notable increase in hazardous waste due to warehouse cleaning. Social initiatives featured the first Family Fun Time parent-child activity and extensive anti-corruption training for employees.
Company: Zhaoke Ophthalmology Ltd
Sector: Health Care
Country: China
Year: 2022
Type: SR
Pages: 46
Zhaoke Ophthalmology Ltd
ESG Report
The report highlights Zhaoke Ophthalmology's commitment to sustainable biotech development, focusing on its drug pipeline of 26 candidates and advanced manufacturing facility in Nansha. In 2022, the Group conducted a materiality assessment identifying nine key topics, including workplace safety and product quality. Environmental efforts included setting targets for waste and energy, with a notable increase in hazardous waste due to warehouse cleaning. Social initiatives featured the first Family Fun Time parent-child activity and extensive anti-corruption training for employees.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2022
Reporting Period
Jan 1, 2022 - Dec 31, 2022
Fiscal Year
2022
Published
Mar 27, 2023
Type
Sustainability Report
Language
English, Chinese
Pages
File Size
Standards & Assurance
Materiality Assessment
Other Standards
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Water Consumption
Total Waste
Workplace Fatalities
Employees